Strensiq
Ended Awarded Last action
- Contract number
- 36C26025F0093
- Awardee
-
Alexion Pharmaceuticals Inc. UEI DKCXLGANZAN3
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $626,866
Award facts
- Contract value 100% obligated
- $626,866.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Carrollton, TX 75010, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$626,807 | |
| Funding Only Action | -$297 | |
| Original award | $1,253,970 |
About this award
Alexion Pharmaceuticals Inc., a Boston-based biopharmaceutical company specializing in rare disease therapeutics, has been awarded a delivery order valued at $626,866.08 by Veterans Integrated Service Network 20 for the supply of Strensiq, a specialized injectable medication used to treat hypophosphatasia, a rare genetic disorder. This delivery order, issued on December 22, 2024, with an ultimate completion date of December 21, 2025, operates under a firm fixed-price structure with no set-aside designation. The contract represents an incremental procurement need under Alexion's existing single-award Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center, valued at $4.24 million and active through August 31, 2026.
The underlying Blanket Purchase Agreement, established under the Pharmaceuticals and Drugs General Services Administration Schedule (FSS-61-IB), streamlines the procurement and delivery of Strensiq to Veterans Affairs medical centers and clinics nationwide, enabling individual Veterans Integrated Service Networks and VA facilities to place delivery orders as needed to ensure continuity of care for veterans requiring this critical rare disease treatment. The arrangement includes pricing update provisions through 2026 to maintain market-based pricing, with work performed directly by Alexion from its Boston facility and a performance location in Carrollton, Texas. This delivery order reflects the active utilization of the BPA structure, demonstrating sustained federal vendor capability in delivering specialized pharmaceutical products to the VA healthcare system.
Quick answers
Who was awarded contract 36C26025F0093?
36C26025F0093 was awarded to Alexion Pharmaceuticals Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on December 22, 2024.
How much is contract 36C26025F0093 worth?
The government has obligated $626,866 on 36C26025F0093.
Is contract 36C26025F0093 an order under another contract?
Yes. 36C26025F0093 is a delivery order under 36F79718D0355, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0093 competed?
The extent of competition for 36C26025F0093 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award